Press enter to see results or esc to cancel.

Inbiomotion

A spin-off of IRB Barcelona and ICREA research labs, Inbiomotion is focused on providing a unique companion diagnostic solution addressing an urgent and unmet medical need in the personalized adjuvant treatment of early-stage breast cancer patients. The company’s unique diagnostic assay is based on a highly selective single-gene predictive biomarker. Data generated thus far points …

Continue Reading

Adcendo

A spin-out from The University of Copenhagen and Rigshospitalet, Adcendo is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (ADCs). The company’s drugs are directed at a target receptor uPARAP, which allows targeted therapy in several cancer forms where expression of the target has been found to be highly unregulated, including …

Continue Reading

Ona Therapeutics

A spin-off from ICREA and Advanced Studies and the IRB Institute for Research in Biomedicine, ONA Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting lipid metabolism in order to treat advanced (metastatic) cancer. The company’s technology is based on pioneering work from Dr Aznar-Benitah published in Nature …

Continue Reading

Nuage Therapeutics

Nuage Therapeutics leverages chemical biology and biomolecular condensation to develop selective drugs targeting proteins with disordered regions for challenging indications to improve patient’s life. Specifically, it uses a proprietary assay to discover new drugs for the treatment of castration-resistant prostate cancer.

Continue Reading

MyPL

MyPL has developed a personalized augmented medicine platform built on a global approach to patient data, which helps healthcare professionals to determine the personalized therapeutic strategies accurately to be implemented for a given patient, particularly in the case of cancer patients. This unique data visualization solution allows a large amount of data as well as …

Continue Reading

Kheiron Medical Technologies

Kheiron Medical is on a mission to help breast cancer patients live longer, better lives through earlier detection. Its solution, called Mia (Mammography Intelligent Assessment), combines new deep learning methods, data science, and radiology insights to help doctors find malignancies in mammograms. Whilst many AI technologies are not designed to be inclusive, Kheiron’s technology has …

Continue Reading

Mindpeak

MindPeak builds automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. Its tools assist cancer experts in providing reliable and reproducible diagnoses. This frees specialists from tedious, repetitive tasks such as the quantification of cells or biomarkers and allows them to focus on tasks where their human expertise is indispensable. The company …

Continue Reading

Elypta

Elypta is a molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome, which are system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer non-invasively. Elypta is advancing a broad clinical program across different cancers, with …

Continue Reading

Terapet

Terapet has developed an add-on device to improve existing proton therapy, which is an advanced form of radiotherapy for cancer treatment that can target tumors with extreme precision. It is a non-invasive medical device placed close to the patient during the treatment to enable doctors to monitor the delivered proton dose inside the patients during …

Continue Reading

Sarcura

Sarcura is developing an instrument platform for the GMP manufacturing of autologous cell therapies. Its platform combines microfluidic processing with silicon chip technology to enable real-time process control and manipulation on a cellular level supporting a fully automated manufacturing system. The company’s target is to scale global manufacturing capacity for patient-specific cell therapy cancer treatments …

Continue Reading

CancerAppy

CancerAppy has developed a platform based on Big Data and AI, specialized in the field of cancer research, developed by and for scientists and drug developers that fills the gap between basic data tools and pharma intelligence tools. Said platform is meant to efficiently and effectively de-risk the process of cancer drug discovery and development …

Continue Reading

Vinehealth

Founded in 2018, Vinehealth has built an app applying behavioral science and AI to deliver highly personalized support for cancer patients at scale. The platform also acts as a channel through which patients can be remotely monitored by their clinicians as they provide feedback on symptoms and report any treatment side effects. On the other …

Continue Reading